Which patients are at the highest risk of dying from competing causes ≤10 years after radical prostatectomy?

BJU International

Volumn 110, Issue 2, 2012, Pages 206-210

  Froehner, Michael ^a   Koch, Rainer ^a   Litz, Rainer J ^a   Hakenberg, Oliver W ^b   Wirth, Manfred P ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Comorbidity; Competing mortality; Prostate cancer; Radical prostatectomy; Selection; Worst case scenarios

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; COMORBIDITY; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; LIFESPAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SURGICAL RISK; SURVIVAL RATE; SURVIVAL TIME;

AGED; CAUSE OF DEATH; COMORBIDITY; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84863448317     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10693.x     Document Type: Article

References (19)

1. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708-17
2. Mohler J, Bahnson RR, Boston B et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200
3. Altekruse SF, Kosary CL, Krapcho M et al. SEER cancer statistics review, 1975-2007, national cancer institute. Bethesda, MD, based on November 2009
4. SEER data submission, posted to the SEER web site, 2010. Available at: http://seer.cancer.gov/csr/1975-2007/. Accessed September 2011.
5. Daskivich TJ, Chamie K, Kwan L et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011; 117: 2058-66
6. Albertsen PC, Moore DF, Shih W et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011; 29: 1335-41
7. Froehner M, Koch R, Wirth MP. Comment on: Daskivich TJ, Chamie K, Kwan L et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011; 117: 2058-66
8. Saklad M. Grading of patients for surgical procedures. Anesthesiology 1941; 2: 281-4
9. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th edn. Boston, Mass: Little, Brown & Co, 1994: 253-6
10. Canadian Cardiovascular Society. Canadian Cardiovascular Society grading of angina pectoris. Available at: http://www.ccs.ca/download/position- statements/Grading%20of%20Angina.pdf. Accessed September 2011.
11. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83 (Pubitemid 17055592)
12. Houterman S, Janssen-Heijnen ML, Hendrikx AJ et al. Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study. Crit Rev Oncol Hematol 2006; 58: 60-7
13. Pintilie M. Competing Risks: A Practical Perspective. Chichester, England; Hoboken, NJ: John Wiley & Sons, 2006: 195-207
14. Walz J, Gallina A, Perrotte P et al. Clinicians are poor raters of lifeexpectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 2007; 100: 1254-8 (Pubitemid 350043902)
15. Walz J, Gallina A, Saad F et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007; 25: 3576-81 (Pubitemid 47372594)
16. Guzzo TJ, Dluzniewski P, Orosco R et al. Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology 2010; 76: 553-8
17. Stephenson AJ, Kattan MW, Eastham JA et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 4300-5
18. Boulos DL, Groome PA, Brundage MD et al. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent. Cancer 2006; 106: 1804-14
19. Alibhai SM, Leach M, Tomlinson GA et al. Is there an optimal comorbidity index for prostate cancer? Cancer 2008; 112: 1043-50 (Pubitemid 351304588)